Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
Inhoud geleverd door Proactive Investors. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Proactive Investors of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
Player FM - Podcast-app
Ga offline met de app Player FM !
Ga offline met de app Player FM !
Analyzing Nanoviricides' Shift to RSV Treatments with Proactive Healthcare Analyst Dr. John Savin
MP3•Thuis aflevering
Manage episode 419438000 series 2891889
Inhoud geleverd door Proactive Investors. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Proactive Investors of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
Proactive Healthcare Analyst Dr John Savin joined Steve Darling to delved into the recent strategic developments at NanoViricides, shedding light on the company's transition from COVID-19 to respiratory syncytial virus (RSV) treatments. Initially known for its polymer antiviral agent targeting COVID-19, NanoViricides garnered attention with clinical trials conducted in India during the height of the pandemic. However, with the decline of COVID-19 cases, the company has shifted its focus towards tackling RSV, a prevalent lung infection. Dr. Savin highlighted the significance of this pivot, considering RSV's substantial market potential and the limited availability of acute therapies. RSV, currently addressed primarily through vaccines and antibody products, presents a lucrative market valued at $3 billion annually, with forecasts suggesting a potential surge to $8 billion within the next decade. Unlike vaccines requiring pre-infection administration, acute therapies for RSV are scarce, creating a ripe opportunity for Nanoviricides to make a meaningful impact. Dr. Savin outlined NanoViricides' pathway in the RSV space, which entails seeking regulatory approval in the United States. Key milestones in this journey include engaging in discussions with the FDA and submitting regulatory dossiers, a process expected to extend into the spring of the following year. Despite facing financial constraints, with only $3.2 million available, Nanoviricides remains undeterred in its pursuit. The company plans to leverage existing loan facilities, explore market opportunities, and even consider mortgaging assets if necessary to fund its anticipated clinical trials. Dr. Savin estimated the trial cost to be at least $5 million USD, earmarked for the 2026 financial year. Encouraging preclinical data bolster NanoViricides' confidence in the potential success of its upcoming trials. Dr. Savin underscored the importance of focusing on a single indication to accumulate substantial clinical data and establish credibility within the medical community and among investors. Overall, NanoViricides' strategic shift towards RSV treatments signals a calculated move to capitalize on a burgeoning market opportunity, leveraging its expertise and resources to address an unmet medical need and potentially revolutionize the landscape of acute viral infection therapeutics. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc #biotec #ClinicalTrials #FDAApproval #NanoVariousSides #COVID19 #VirusTreatment #PolymerAntiviral #USRegulatory #VaccineMarket #Biotechnology #HealthcareFunding #MedicalResearch #PreclinicalData #InfectionTreatment #BiotechFunding #USHealthcare #AntiviralResearch #HealthInnovation #RSVTreatment #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
608 afleveringen
MP3•Thuis aflevering
Manage episode 419438000 series 2891889
Inhoud geleverd door Proactive Investors. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Proactive Investors of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
Proactive Healthcare Analyst Dr John Savin joined Steve Darling to delved into the recent strategic developments at NanoViricides, shedding light on the company's transition from COVID-19 to respiratory syncytial virus (RSV) treatments. Initially known for its polymer antiviral agent targeting COVID-19, NanoViricides garnered attention with clinical trials conducted in India during the height of the pandemic. However, with the decline of COVID-19 cases, the company has shifted its focus towards tackling RSV, a prevalent lung infection. Dr. Savin highlighted the significance of this pivot, considering RSV's substantial market potential and the limited availability of acute therapies. RSV, currently addressed primarily through vaccines and antibody products, presents a lucrative market valued at $3 billion annually, with forecasts suggesting a potential surge to $8 billion within the next decade. Unlike vaccines requiring pre-infection administration, acute therapies for RSV are scarce, creating a ripe opportunity for Nanoviricides to make a meaningful impact. Dr. Savin outlined NanoViricides' pathway in the RSV space, which entails seeking regulatory approval in the United States. Key milestones in this journey include engaging in discussions with the FDA and submitting regulatory dossiers, a process expected to extend into the spring of the following year. Despite facing financial constraints, with only $3.2 million available, Nanoviricides remains undeterred in its pursuit. The company plans to leverage existing loan facilities, explore market opportunities, and even consider mortgaging assets if necessary to fund its anticipated clinical trials. Dr. Savin estimated the trial cost to be at least $5 million USD, earmarked for the 2026 financial year. Encouraging preclinical data bolster NanoViricides' confidence in the potential success of its upcoming trials. Dr. Savin underscored the importance of focusing on a single indication to accumulate substantial clinical data and establish credibility within the medical community and among investors. Overall, NanoViricides' strategic shift towards RSV treatments signals a calculated move to capitalize on a burgeoning market opportunity, leveraging its expertise and resources to address an unmet medical need and potentially revolutionize the landscape of acute viral infection therapeutics. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc #biotec #ClinicalTrials #FDAApproval #NanoVariousSides #COVID19 #VirusTreatment #PolymerAntiviral #USRegulatory #VaccineMarket #Biotechnology #HealthcareFunding #MedicalResearch #PreclinicalData #InfectionTreatment #BiotechFunding #USHealthcare #AntiviralResearch #HealthInnovation #RSVTreatment #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
608 afleveringen
All episodes
×Welkom op Player FM!
Player FM scant het web op podcasts van hoge kwaliteit waarvan u nu kunt genieten. Het is de beste podcast-app en werkt op Android, iPhone en internet. Aanmelden om abonnementen op verschillende apparaten te synchroniseren.